Ryanair Gains on Narrower Net Loss; Regeneron Melanoma Trial Failure | Stock Movers
On this episode of Stock Movers with Alexis Christoforous: - NextEra Energy (NEE) agreed to pay about $67 billion in stock for Dominion Energy (D) in the biggest power acquisition ever, creating a giant utility extending from Florida to the data centers clustered in Virginia. The deal would give NextEra a swathe of electricity assets stretching across Virginia and the Carolinas. - Ryanair (RYAAY) gains as it delivered a decent end to the year, but flagged impact ahead from rising costs. The airline said unit costs for 2027 could increase by a mid-single digit percentage, with concerns over current unhedged jet fuel prices, and also impact from higher crew and aircraft maintenance costs. - Regeneron Pharmaceuticals (REGN) shares drop after the drugmaker’s phase 3 data for fianlimab in metastatic melanoma fell short of expectations. Citi downgraded its rating on the stock following the “disappointing” trial update. (Source: Bloomberg)المصدر: Bloomberg | Source: Bloomberg
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة Bloomberg. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by Bloomberg. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.

